Guo Wei Hong, Tian Lina, Dallmann Margaret J, Tam Paul K H
Division of Paediatric Surgery, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong SAR, P.R. China.
Transplantation. 2003 Jun 15;75(11):1895-7. doi: 10.1097/01.TP.0000065294.04793.11.
Small bowel allografts can either be placed heterotopically or orthotopically. In heterotopic small bowel transplantation (H-SBT), the host small intestine containing a substantial amount of gut-associated lymphoid tissue is removed, whereas in conventional orthotopic small bowel transplantation (O-SBT) it is retained. This study compared the allograft survival of H-SBT and O-SBT and evaluated the effect of retaining the host intestine in O-SBT in an altered O-SBT (AO-SBT) model.
SBT was performed in a high-responder rat stain combination (blood group D Agouti --> Lewis). Immunosuppressive treatment consisting of a short course of FK506 (2 mg/kg/day IM for 3 days before transplantation and 0.3 mg/kg/day for 14 days after transplantation) was used.
Survival (mean +/- SD) of H-, O-, and AO-SBT untreated animals was 6.25+/-0.58 days, 6.5+/-0.58 days, and 6.7+/-0.25 days, respectively. With FK506 immunosuppression, survival of H-SBT animals was 49.3+/-13.17 days, whereas 75% (12/16) and 80% (4/5), respectively, of O-SBT and AO-SBT animals achieved indefinite survival (>120 days) with functioning grafts.
Our data suggest that heterotopic placement of intestinal allografts results in a more severe graft rejection than orthotopic placement. The indefinite survival of O-SBT is not due to of the removal of host intestine carrying a heavy load of gut-associated lymphoid tissue.
小肠同种异体移植可异位或原位进行。在异位小肠移植(H-SBT)中,含有大量肠道相关淋巴组织的宿主小肠被切除,而在传统原位小肠移植(O-SBT)中则予以保留。本研究比较了H-SBT和O-SBT的同种异体移植物存活情况,并在改良的O-SBT(AO-SBT)模型中评估了在O-SBT中保留宿主小肠的效果。
在高反应性大鼠品系组合(血型D 刺鼠→刘易斯大鼠)中进行小肠移植。采用由短期FK506组成的免疫抑制治疗(移植前3天2mg/kg/天肌肉注射,移植后14天0.3mg/kg/天)。
未治疗的H-SBT、O-SBT和AO-SBT动物的存活时间(平均值±标准差)分别为6.25±0.58天、6.5±0.58天和6.7±0.25天。使用FK506免疫抑制后,H-SBT动物的存活时间为49.3±13.17天,而O-SBT和AO-SBT动物分别有75%(12/16)和80%(4/5)实现了移植物功能正常的长期存活(>120天)。
我们的数据表明,小肠同种异体移植物的异位植入比原位植入导致更严重的移植物排斥反应。O-SBT的长期存活并非由于切除了携带大量肠道相关淋巴组织的宿主小肠。